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Treatment of advanced melanoma with combined PD-1/CTLA-4 blockade commonly causes
serious immune-mediated complications. Here, we identify a subset of patients predisposed
to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion
of effector memory CD4+ T cells (TEM cells). Pre-therapy CD4+ TEM cell expansion occurs
primarily during autumn or winter in patients with metastatic disease and high cytomega-
lovirus (CMV)-specific serum antibody titres. These clinical features implicate metastasis-
dependent, compartmentalised CMV reactivation as the cause of CD4+ TEM expansion.
Pre-therapy CD4+ TEM expansion predicts hepatitis in CMV-seropositive patients, opening
possibilities for avoidance or prevention. 3 of 4 patients with pre-treatment CD4+ TEM
expansion who received αPD-1 monotherapy instead of αPD-1/αCTLA-4 therapy remained
hepatitis-free. 4 of 4 patients with baseline CD4+ TEM expansion given prophylactic val-
ganciclovir and αPD-1/αCTLA-4 therapy remained hepatitis-free. Our findings exemplify how
pathogen exposure can shape clinical reactions after cancer therapy and how this insight
leads to therapeutic innovations.
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Treatment with anti-programmed cell death protein-1 (αPD-1) alone or combined with anti-cytotoxic T-lymphocyte-associated protein 4 (αCTLA-4) has greatly improved the
prognosis of metastatic melanoma with a substantial fraction of
patients achieving long-lasting partial or complete clinical
responses1–6. The principal limitation of αPD-1/αCTLA-4 dual
therapy is the relatively high rate of immune-related complica-
tions, which commonly include colitis, hepatitis and thyroiditis,
but may also include pneumonitis, myocarditis and encephalitis7,8.
Such adverse events range from mild reactions to life-threatening
presentations, but are nevertheless clinically significant incidents
that influence patient management9,10. Avoidance of complica-
tions has led to a somewhat complicated treatment decision-
making process (Fig. 1a) that seeks to balance individual risk and
capacity to tolerate adverse reactions against the superior clinical
responses achieved with dual αPD-1/αCTLA-4 therapy over
αPD-1 monotherapy11–13.
Our aetiological understanding of colitis, hepatitis and thyr-
oiditis caused by immune checkpoint blockade remains incom-
plete14; however, these treatment-related conditions are clearly
different from known autoimmune diseases15,16. Such adverse
reactions are usually attributed to generalised dysregulation of
T cells17,18 or autoantibodies15. Here, we explore a different
view—namely, that individual patients are predisposed to parti-
cular treatment-related complications by virtue of pathogen-
specific memory T cells present in their repertoire before immune
checkpoint blockade is given.
Cytomegalovirus (CMV) seroprevalance amongst European
adults is over 50%. Primary CMV infection usually presents
during young adulthood as an acute febrile illness, after which
life-long latency is established. The exact sites and mechanisms of
CMV latency are not fully resolved, but myelomonocytic cells in
blood and tissues are major reservoirs19. CMV reactivation
characteristically follows immune compromise caused by
immunosuppressive therapy or other viral infections20. Clinical
manifestations of CMV reactivation are variable, ranging from
classic febrile illness to tissue-invasive disease presenting as
colitis, hepatitis, pneumonitis or encephalitis21. Reactivation of
CMV causes cellular injury through the cytopathic effect of viral
replication, but more conspicuously through triggering T cell
immunity. Pneumonitis in transplant recipients illustrates how
CMV-reactive T cells provoke extensive, life-threatening inflam-
mation despite low-level viral replication22. Even in anatomical
locations from which T cells are normally excluded, such as the
retina, T cell-mediated responses significantly contribute to
CMV-related disease. Thus, low-level and compartmentalised
reactivation of CMV can be responsible for serious acute
immunopathology in humans23–25.
Cycles of CMV latency and reactivation lead to a now well-
recognised phenomenon of memory inflation, which is typified by
failure of primed CMV-specific CD8+ T cell populations to
contract and give rise to central memory T cells26. Instead, a
dominant pool of effector memory CD8+ T cells that does not
become functionally exhausted is maintained27. Such inflationary
CD8+ T cells achieve high frequencies over time, sustained
through repetitive stimulation by viral reactivation or long-term
persistence of viral antigens28. Memory inflation is described as
an exclusive feature of CD8+ effector T cell responses, although
durable expansion of CMV-specific CD4+ T cells can occur in
transplant recipients29.
This study identifies pre-therapy expansion of CD4+ effector
memory T cells (TEM) in CMV-infected patients with metastatic
melanoma as a prognostic marker of αPD-1/αCTLA-4-related
hepatitis. Opting for αPD-1 monotherapy or prophylactic val-
ganciclovir in CMV IgG+ patients with unresectable metastatic
disease and pre-treatment expansion of CD4+ TEM cells reduces
their risk of hepatitis. We conclude that sub-clinical reactivation
of CMV plays a previously unsuspected role in the immuno-
pathogenesis of αPD-1/αCTLA-4-related hepatitis in a subgroup
of patients.
Results
Clinical features do not predict αPD-1/αCTLA-4-related hepa-
titis. If immune-related complications of αPD-1/αCTLA-4 ther-
apy resulted solely from treatment-induced immunological
effects30,31, we might expect hepatitis, colitis and thyroiditis to
coincide often32 (Fig. 1b). However, no such associations were
found in a cohort of 89 patients with metastatic melanoma treated
with αPD-1/αCTLA-4 dual therapy (Fig. 1c, Supplementary Fig. 1
and Supplementary Tables 1–3). This raises the possibility that
some individuals are predisposed to particular adverse reactions.
In this study, we focused on factors that predispose to αPD-1/
αCTLA-4-related hepatitis. Except for patients who developed
hepatitis being generally younger (Supplementary Table 4) no
associations were found between incidence of hepatitis and pre-
treatment clinical variables (Supplementary Tables 4 and 5).
Conventional biochemical markers of liver dysfunction, systemic
inflammation or tumour burden did not discriminate between
patients who did or did not develop hepatitis (Fig. 1d–j). We found
no associations between incidence of hepatitis and seropositivity for
hepatitis B virus (HBV), hepatitis C virus (HCV) or hepatitis E virus
(HEV; Fig. 1k–m). Incidence of hepatitis was not greater with more
rounds of αPD-1/αCTLA-4 therapy; in fact, as immune-related
complications are reason to withhold treatment, patients who
developed hepatitis tended to receive fewer rounds of αPD-1/
αCTLA-4 (Fig. 1n). Autoimmune hepatitis-related autoantibodies
were not associated with risk of hepatitis (Supplementary Table 6).
In short, case history and routine clinical investigations did not
predict hepatitis after dual therapy in our study cohort.
CD4+ TEM cell expansion predicts αPD-1/αCTLA-4-related
hepatitis. We next profiled circulating leucocyte subsets imme-
diately prior to start of dual therapy in a training set of n= 44
patients with unresectable metastatic melanoma (Supplementary
Figs. 2–8). Comparing the frequency of 50 principal leucocyte
subsets between patients who subsequently did (n= 18) or did
not (n= 26) develop hepatitis revealed significant over-
representation of CD4+ TEM cells associated with hepatitis
(Fig. 2a, b). This observation was confirmed in a validation set
(n= 45) of similar patients (Fig. 2c). Baseline expansion of CD4+
TEM cells was a fair discriminator (AUROC= 0.706) of patients
who did or did not later develop hepatitis in the validation set
(Fig. 2d). Strikingly, CD4+ TEM cell frequencies in all patients
with completely resected disease were normally distributed with
no extreme cases of baseline CD4+ TEM cell expansion, allowing
us to set a threshold below which 99% of patients should fall
(Fig. 2e). Applying this stringent cut-off to our validation cohort
of patients with unresectable metastatic disease (Fig. 2f) allowed
us to correctly predict hepatitis in 6 of 6 patients with CD4+
TEM≥21% (specificity= 100%) and correctly identify 6 of 20
patients who developed hepatitis (sensitivity= 30.0%). CD4+
TEM≥21% patients were not predisposed to colitis (Fig. 2g), thyr-
oiditis or superior clinical responses to therapy (Supplementary
Table 7). Hepatitis was not more severe in CD4+ TEM≥21%
patients compared to CD4+ TEM<21% patients (Fig. 2h) and no
difference in time-to-first presentation was observed (Fig. 2i).
Hence, baseline CD4+ TEM expansion is a specific, but relatively
insensitive prognostic marker of individuals who are predisposed
to hepatitis after αPD-1/αCTLA-4 therapy. Owing to its low
sensitivity, classifying patients as CD4+ TEM<21% has limited
clinical utility; however, specifically identifying cases at high-risk
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of hepatitis before treatment is useful from a research perspective
because we can then prospectively study the immunological basis
of their predisposition.
Opting for αPD-1 monotherapy reduces risk of hepatitis.
Although αPD-1 monotherapy achieves fewer sustained clinical
responses in patients with metastatic melanoma, it causes fewer
adverse reactions than αPD-1/αCTLA-4 dual therapy1. Therefore,
there is a clear rationale for avoiding αPD-1/αCTLA-4 dual
therapy in patients at risk of hepatitis. Four CD4+ TEM≥21%
patients with metastasic disease presented during our study, but
were electively treated with αPD-1 monotherapy (Fig. 2j).
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Whereas 12 of 12 CD4+ TEM≥21% patients treated with αPD-1/
αCTLA-4 dual therapy developed hepatitis, 3 of 4 CD4+ TEM≥21%
patients who received αPD-1 monotherapy remained hepatitis
free. Reducing the incidence hepatitis by opting for αPD-1
monotherapy hints that CTLA-4 blockade may be mechan-
istically important for development of hepatitis in CD4+
TEM≥21% patients33.
CD4+ TEM frequency is an independent predictor of hepatitis.
We next investigated possible causes of baseline CD4+ TEM
expansion. To establish CD4+ TEM expansion as an independent
risk factor, we first sought to exclude possible confounding cov-
ariables. Baseline CD4+ TEM≥21% was not related to sex, age or
body-mass index (Supplementary Table 7 and Fig. 3a, b). No
significant correlation was observed between baseline CD4+
TEM % and serum levels of C-reactive protein (CRP), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transferase (γ-GT) or total bilirubin (Fig. 3c–g).
Because glucose metabolism provides a reliable measure of liver
inflammation34, we were able to further rule out liver inflam-
mation prior to therapy as a predisposing cause of CD4+
TEM≥21% hepatitis by estimating hepatic glucose uptake in
patients who underwent 18F-fluoro-2-deoxy-D-glucose (18F-FDG)
PET/CT studies as part of routine tumour staging shortly before
starting immunotherapy (Fig. 3h). This retrospective comparison
showed 18F-FDG standard uptake ratios (SURmean liver) were
higher in CD4+ TEM<21% patients than CD4+ TEM≥21% patients
with hepatitis (Fig. 3i). Therefore, our biochemical and radi-
ological investigations argue against pre-treatment liver inflam-
mation as a common cause for baseline CD4+ TEM expansion
and treatment-related hepatitis.
Because CD4+ TEM expansion is principally a feature of
metastatic melanoma (Fig. 2e), we next asked whether CD4+
TEM% was somehow associated with tumour burden. No
relationship was found between CD4+ TEM% and the number
of organs containing metastases, presence of hepatic metastases
or serum lactate dehydrogenase (LDH) and protein-S100 serum
levels (Fig. 3j–m and Supplementary Table 7). There was a
tendency for CD4+ TEM≥21% patients to have received previous
therapy of any type (including BRAFi/MEKi or Talimogen
laherparepvec) but besides implying a longer disease course
before starting dual therapy, we see no mechanistic interpreta-
tion because these drugs share no common pharmacological
action (Fig. 3n). In short, we found no obvious clinical
association to explain the predisposition of CD4+ TEM≥21%
patients to hepatitis.
CD4+ TEM cell expansion is associated with chronic T cell acti-
vation. Although CD4+ T cell counts were not different between
CD4+ TEM<21% and CD4+ TEM≥21% patients (Supplementary
Table 7), there were significantly fewer circulating naïve T cells in
CD4+ TEM≥21% patients (Fig. 4a). This reduction was com-
plemented by increased absolute numbers of CD4+ TEM and TEMRA
cells (Fig. 4b, c) whereas central memory T cell (TCM) counts
tended to be lower in CD4+ TEM≥21% patients (Fig. 4d). We next
defined other leucocyte subsets that correlated with
CD4+ TEM % in both our training and validation cohorts (Fig. 4e).
Most covariant populations were T cells, particularly CD4+ T cell
subsets. Changes in the CD4+ T cell compartment of TEM≥21%
patients were consistent with chronic activation, particularly
downregulation of CD27 and upregulation of CD57, HLA-DR and
CD279 expression (Fig. 4f–i). Similar differences were detected in
CD8+ T cells (Supplementary Fig. 9). Notably, CD4+ TEM≥21%
patients tended to have higher frequencies of CD160+ CD244+
exhausted CD8+ T cells than CD4+ TEM<21% patients (Fig. 4j).
Most adults are persistently infected with Torque Teno Virus
(TTV), a non-enveloped, circular, single-stranded DNA virus of
the Anellovirus family that causes no apparent disease. T cell
immunity controls TTV replication in healthy people, whereas
TTV copy number in immunocompromised individuals is
increased; therefore, TTV load in plasma is a useful marker of
immune competence. Despite accumulating chronically activated
and exhausted T cells, TTV load in CD4+ TEM≥21% versus CD4+
TEM<21% patients was not different, implying that CD4+ TEM≥21%
patients are not generally immunocompromised (Fig. 4k).
CD4+ TEM cell expansion correlates with immunity to CMV.
To briefly summarise, baseline expansion of CD4+ TEM cells
identifies a subset of patients with metastasic melanoma who
are predisposed to αPD-1/αCTLA-4-related hepatitis. These
patients show signs of persistent or recurrent CD4+ and CD8+
T cell responses35, but are otherwise clinically and immunolo-
gically unremarkable. It is usually very difficult to isolate factors
responsible for such a non-specific immunological picture36.
Fortunately, a surprising pattern emerged from our dataset:
CD4+ TEM≥21% patients mostly presented between September
and February (Fig. 5a). This seasonal influence was apparent
over all 4 years of the study, leading us to think that CD4+ TEM
expansion might be driven by a pathogen. Active infections with
hepatitis viruses, including HBV and HCV, are relative con-
traindications to αPD-1/αCTLA-4 therapy (Supplemen-
tary Table 7), so we were forced to consider possible
involvement of other hepatotropic viruses, such as HEV and
herpesgroup viruses.
Fig. 1 Individual predisposition to hepatitis after αPD-1/αCTLA-4 treatment. a Individualised treatment of melanoma is guided by tumour staging,
presence of B-RAF mutations and fitness-for-toxicity. b Colitis, hepatitis and thyroiditis are common immune-related complications of dual therapy with
Nivolumab plus Ipilimumab; 31.4% of patients experienced two or more of these immune-related adverse reactions (n= 89). c Colitis, hepatitis and
thyroiditis occurred independently and were not significantly associated with clinical response (n= 89; F.E). d–h Patients who developed hepatitis of any
grade following dual therapy lacked biochemical signs of liver inflammation before treatment. In particular, no clinically meaningful differences in plasma
levels of d aspartate transaminase (AST; n= 87; M.W.; Bonferroni-corrected p-value, m= 5), e alanine transaminase (ALT; n= 89; M.W.; Bonferroni-
corrected p-value, m= 5), f gamma glutamyl transaminase (γ-GT; n= 89; M.W.; Bonferroni-corrected p-value, m= 5), g total bilirubin (n= 87; M.W.;
Bonferroni-corrected p-value, m= 5), or h C-reactive protein (CRP; n= 85; M.W.; Bonferroni-corrected p-value, m= 5) were observed between patients
who developed hepatitis and those who did not. Median values are indicated by a red line. i, j Biochemical markers of tumour burden were not different
between patients who developed hepatitis and those who did not. i Pre-treatment levels of lactate dehydrogenase (n= 89; M.W.; Bonferroni-corrected
p-value, m= 4). Median values are indicated by a red line. j Pre-treatment levels of protein S100 (n= 89; M.W.; Bonferroni-corrected p-value, m= 4).
k–m No association was observed between seropositivity for k hepatitis B virus core antigen (HBcAg; n= 85; F.E.; Bonferroni-corrected p-value, m= 3),
l hepatitis C virus (HCV; n= 85; F.E.; Bonferroni-corrected p-value, m= 3), or m hepatitis E virus (HEV; n= 67; F.E.; Bonferroni-corrected p-value, m= 3)
and development of hepatitis following dual therapy. n No association was observed between rounds of αPD-1/αCTLA-4 administered and development of
hepatitis (n= 89; M.W.).
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Latent CMV infection is prevalent amongst European adults
and involves many organs, including liver. Compartmentalised
reactivation of CMV infection occurs in immunocompromised
individuals and those with concomitant viral upper respiratory
tract infections20. In our patients, we found a strong association
between serum CMV-specific IgG antibody levels and CD4+ TEM
status (Fig. 5b). Furthermore, T cell reactivity against CMV pp65
peptides in an IFN-γ enzyme-linked immunospot (ELISPOT)
assay was tightly associated with CD4+ TEM status (Fig. 5c).
These results led us to hypothesise a causal relationship between
compartmentalised, sub-clinical CMV reactivation in liver and
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Fig. 2 Circulating CD4+ T effector memory cell frequency predicts hepatitis after Nivolumab plus Ipilimumab treatment. a Peripheral blood samples
were collected from melanoma patients with metastatic disease receiving αPD-1/αCTLA-4 therapy immediately before administration of the first dose
(n= 89). Leucocyte subsets differentially represented in patients with or without hepatitis were identified in a randomly assigned training set (B.H.-
corrected t-tests; n= 44; m= 50; FDR= 0.25). Red dots indicate significantly differently represented subsets. Example gating strategies for analysis of
flow cytometry data are provided as Supplementary Figs. 2–8. b CD4+ TEM % in training set patients with or without treatment-related hepatitis (n= 44;
M.W.). Median values are indicated by a red line. c CD4+ TEM % in validation set patients with or without treatment-related hepatitis (n= 45; M.W.).
d ROC analysis of CD4+ TEM % as a discriminatory marker for treatment-related hepatitis in the validation set (n= 45). e Comparison of the bimodal
distribution of CD4+ TEM % in patients with unresectable metastatic disease (n= 107) and the normal distribution (n= 49; K2= 2.79; p= 0.248) of
CD4+ TEM % in patients with completely resected tumours. A cut-off of CD4+ TEM≥ 21% was set (indicated by a dashed red line) below which 99% of
completely resected tumour cases should fall. Four pink points represent CD4+ TEM≥21% patients with metastatic disease who were electively treated with
αPD-1 monotherapy. f In the validation set, 68.9% patients were correctly classified using a cut-off of CD4+ TEM≥ 21 %, whereas 55.6% were correctly
classified under the no-information model (n= 45; F.E.). g CD4+ TEM≥ 21 % is not a marker of predisposition to αPD-1/αCTLA-4-related colitis (n= 89;
F.E.). h CD4+ TEM≥21% patients did not experience more severe hepatitis than CD4+ TEM<21% patients (n= 38; F.E.). Dashed red line indicates a cut-off of
CD4+ TEM≥ 21%. i Time-to-first presentation of hepatitis was not different between CD4+ TEM≥21% (n= 12) and TEM<21% (n= 26) patients (log-rank).
j Twelve of 12 patients with unresectable metastatic melanoma and CD4+ TEM≥ 21% developed hepatitis after αPD-1/αCTLA-4 dual therapy. By contrast,
3 of 4 CD4+ TEM≥21% patients treated with αPD-1 monotherapy did not develop hepatitis (F.E.; p= 0.007).
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Because baseline CD4+ TEM cell expansion was mainly a
feature of CMV IgG+ patients (Fig. 5d), we next asked whether
incorporating CMV IgG status could improve our predictive
model. When considering only CMV IgG+ cases, CD4+ TEM %
was a more discriminatory marker of hepatitis (Fig. 5e).
Therefore, using our training set filtered for CMV IgG+ cases,
we revised our cut-off to CD4+ TEM ≥ 16% in CMV IgG+ cases in
order to achieve a better compromise between specificity and
sensitivity (Supplementary Fig. 10). The new cut-off performed
well in the validation set with a correct classification rate of 81.0%
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(positive predictive value (PPV)= 85.7% and negative predictive
value (NPV)= 78.6%) compared to 42.9% under the no-
information model.
For descriptive purposes, we can consider the distribution of
patients from the combined training and validation sets according
to CMV IgG and CD4+ TEM status (Fig. 5f). Our predictive
model explains the occurrence of hepatitis in 34 of 89 (38.2%) of
all patients (red boxes). Two of 17 (12%) CMV IgG+ CD4+
TEM≥16% patients (green box) did not develop hepatitis: one of
these received four rounds of αPD-1/αCTLA-4 therapy and
registered no complications; however, the other received only 1
round of αPD-1/αCTLA-4 before treatment with prednisolone
from weeks 2 to 7 for colitis. We speculate 4 of 23 CMV IgG+
CD4+ TEM<16% patients who were incorrectly predicted as
hepatitis-negative (pink box) were sampled at an early stage of
CD4+ TEM cell expansion and our test was not sensitive enough
to discriminate the change. Our model does not explain why 19 of
49 CMV IgG− patients developed hepatitis (blue box) but we
believe these represent an aetiologically distinct subset.
CMV-reactive CD4+ T cells are enriched in CD4+ TEMhigh
patients. We next asked whether CMV-reactive CD4+ T cells
were enriched in patients with baseline CD4+ TEM expansion.
Peripheral blood mononuclear cells (PBMC) were stimulated in
culture for 18 h with CMV lysates before IFN-γ, TNFα, IL-17, IL-
4 and CD69 expression was measured by flow cytometry (Fig. 6a
and Supplementary Figs. 11 and 12). To detect hyporesponsive
CMV-specific T cells, paired cultures were also stimulated in the
presence of neutralising antibodies against PD-1 and CTLA-4. In
contrast to CMV IgG− and CMV IgG+ CD4+ TEM<16% patients,
we readily detected IFN-γ-producing, CMV-reactive CD4+
T cells in CMV IgG+ CD4+ TEM≥16% patients (Fig. 6b). This
difference implies a higher number of circulating IFN-γ-produ-
cing, CMV-reactive CD4+ T cells (Fig. 6c). Proportions of CMV-
reactive CD4+ T cells expressing IL-17, IL-4 or only TNFα were
too low to quantify accurately.
Valganciclovir reverses αPD-1/αCTLA-4-related hepatitis.
Strong associations between T cell immunity against CMV,
expansion of CD4+ TEM and risk of treatment-related hepatitis
imply an underlying pathogenic mechanism; however, to
demonstrate a causal relationship, we needed to establish that
inhibiting CMV replication was effective in treating or preventing
hepatitis. Valganciclovir is an anti-viral agent licensed for therapy
and prophylaxis of CMV infections in immunocompromised
patients. It is a widely used and safe drug with a well-known and
broadly acceptable profile of adverse effects. Therefore, we next
gave valganciclovir treatment to two patients with αPD-1/
αCTLA-4-related hepatitis.
The first patient was a comparatively fit 54-year-old man with
a new diagnosis of metastatic melanoma (Fig. 7a). Staging CT
revealed multiple lung and bone metastases, but no metastasis to
liver or lymph nodes. At baseline, the patient was CMV-IgG+ and
CD4+ TEM= 18.7% (Fig. 7b). Nivolumab plus Ipilimumab were
given at 0, 3 and 6 weeks. A fourth round of αPD-1/αCTLA-4 at
week 9 was omitted owing to joint pain and the patient received
two rounds of Denosumab (αRANKL). Nivolumab monotherapy
was administered in weeks 12, 16, 20 and 24. Staging CT at week
14 showed a partial clinical response with significant regression of
pulmonary metastases; hence, checkpoint blockade was of clear
clinical benefit.
The patient received a dose of αPD-1 monotherapy in week 32.
Four weeks later, he presented in clinic with grade 4 hepatitis.
Strong reactions against pp65 and IE-1 peptides were measured
by ELISPOT. Accordingly, the patient was treated with 900 mg/
day valganciclovir plus prednisolone. Liver function tests (LFTs)
returned to normal, so over the subsequent 2 weeks, prednisolone
was weaned and then valganciclovir was withdrawn. Seven days
later, the patient returned to clinic with deranged LFTs.
Valganciclovir and prednisolone were both reinstated, leading
to a rapid normalisation of LFTs. Two days later, a for-cause liver
biopsy was performed (Fig. 7c–e). The tissue was essentially
normal, although a few dying hepatocytes and isolated lympho-
cytes were observed in the portal areas. Immunohistochemical
staining for CMV and nested CMV PCR from fixed biopsy
material were negative. The patient remained clinically stable for
9 days, so he was again weaned from prednisolone by the start of
week 43; however, on this occasion, 900 mg/day valganciclovir
treatment was continued. After complete withdrawal of pre-
dnisolone, while still receiving valganciclovir, the patient’s LFTs
remained stable for a further 4 weeks. At the start of week 47,
valganciclovir was withdrawn for a second time. Subsequently,
the patient did not develop hepatitis and required no further
steroids. The patient received further doses of αPD-1 mono-
therapy in weeks 54 and 58 without signs of recurrent liver injury.
To us, this suggests the T cell antigens driving hepatitis in this
patient were absent after valganciclovir treatment. In our clinical
opinion, despite the absence of detectable virus, the patient’s fast
recovery and unusual relapse of hepatitis are best explained by
introduction, withdrawal and reintroduction of valganciclovir.
The second patient was a 49-year-old man who had an
uncomplicated first year after αPD-1/αCTLA-4 and had been
receiving Encorafenib/Binimetinib therapy for 7 weeks when he
developed hepatitis in week 67 (Fig. 8a, b). Hepatitis failed to
resolve despite withdrawal of B-RAFi/MEKi and escalating doses
of prednisolone. 900 mg/day valganciclovir was introduced at the
start of week 72 and a for-cause biopsy was performed on the
same day (Fig. 8b). Four days later, the patient started a course of
1 mg/day mycophenolate mofetil. Strikingly, AST, ALT and γ-GT
Fig. 3 CD4+ TEM frequency is an independent predictor of αPD-1/αCTLA-4-related hepatitis. a CD4+ TEM % did not correlate with age (n= 89;
Pearson). Dashed red line indicates a cut-off of CD4+ TEM≥ 21%. b CD4+ TEM % did not correlate with body mass index (n= 89; Pearson). c CD4+ TEM %
did not correlate with C-reactive protein (CRP) levels (n= 85; Pearson). d CD4+ TEM % did not correlate with aspartate aminotransferase (AST) levels
(n= 87; Pearson). e CD4+ TEM % did not correlate with alanine aminotransferase (AST) levels (n= 89; Pearson). f CD4+ TEM % did not correlate with
gamma-glutamyltransferase (γ-GT) levels (n= 89; Pearson). g CD4+ TEM % did not correlate with total bilirubin levels (n= 89; Pearson). h Glucose
metabolism measured by 18F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake in PET/CT studies is a quantitative marker of liver inflammation. Calculating
standard uptake ratio (SURmean Liver) allows accurate quantification of 18F-FDG uptake in liver by correcting for differential clearance of tracer from blood
and liver parenchyma. Higher SURmean Liver values indicate more severe inflammation. T0= reference time point at 75min post-injection and T= actual
scan time. i SURmean Liver was lower in CD4+ TEM≥21% patients than CD4+ TEM<21% patients who developed hepatitis indicating less inflammation at
baseline in the CD4+ TEM≥21% subgroup (n= 28; Pearson). j CD4+ TEM≥21% was not associated with the number of organs containing one or more
metastases ≥1.5 cm in diameter (n= 103; F.E.). k CD4+ TEM≥21% was not associated with the presence of hepatic metastases (n= 103; F.E.). l CD4+
TEM % did not correlate with lactate dehydrogenase (LDH) levels (n= 88; Pearson). m CD4+ TEM % did not correlate with protein S100 levels (n= 88;
Pearson). n CD4+ TEM≥21% was not associated with any prior therapy (n= 89; F.E.).
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Fig. 4 CD4+ TEM cell enrichment is associated with chronic activation and increased numbers of effector memory CD4+ T cells. a–d Increased CD4+
TEM frequency before treatment reflects a decrease in circulating naïve CD4+ T cells and an increase in circulating numbers of CD4+ TEM cells. a Baseline
naïve CD4+ T cell counts (n= 103; M.W.; Bonferroni correction: m= 4, p= 5.2 ⨯ 10−5). b Baseline CD4+ TEM cell counts (n= 103; M.W.; Bonferroni
correction: m= 4, p= 8.0 ⨯ 10−4). c Baseline CD4+ TEMRA cell counts (n= 103; M.W.; Bonferroni-corrected p-value, m= 4). d Baseline CD4+ TCM cell
counts (n= 103; M.W.; Bonferroni-corrected p-value, m= 4). Median values are indicated by a red line. e Pairwise correlations between CD4+ TEM cell
frequency and other leucocyte subset frequencies in the training and validation sets (n= 103; Pearson). Example gating strategies for analysis of flow
cytometry data are provided as Supplementary Figs. 2–8. f Baseline CD27+ CD4+ T cell frequencies (n= 103; M.W.; Bonferroni correction: m= 60, p=
4.2 ⨯ 10−10). g Baseline CD57+ CD4+ T cell frequencies (n= 103; M.W.; Bonferroni correction: m= 60, p= 2.0 ⨯ 10−9). h Baseline HLA-DR+ CD4+ T cell
frequencies (n= 103; M.W.; Bonferroni correction: m= 60, p= 4.1 ⨯ 10−5). i Baseline CD279+ CD4+ T cell frequencies (n= 103; M.W.; Bonferroni-
corrected p-value, m= 60). j Baseline CD160+ CD244+ CD8+ T cell frequencies (n= 103; M.W.; Bonferroni-corrected p-value, m= 60). k Baseline
Torque Teno Virus (TTV) loads. Uninfected patients were censored from analysis (n= 74; M.W.; Bonferroni-corrected p-value, m= 60). Median values
are indicated by a red line.
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levels declined consistently from the day after valganciclovir was
given, although total bilirubin continued to rise. Starting
valganciclovir treatment appeared to be temporally related to
increased reactivity in CMV IE-1 ELISPOT and a small decline in
CD4+ TEM frequency.
Liver biopsy revealed dense infiltration by lymphocytes,
eosinophils and neutrophils with an accompanying ductal
reaction (Fig. 8c–e). Extensive centrilobular hepatocyte necrosis
was observed, which was also associated with inflammatory
infiltration. These histopathological signs of significant liver
damage could have been consistent with autoimmunity or viral
infection. Both histological staining for CMV and CMV PCR
from fixed biopsy material were negative. Although we were
unable to detect virus, it is our clinical impression that markers of
liver damage responded to valganciclovir treatment.
Valganciclovir prophylaxis prevents αPD-1/αCTLA-4-related
hepatitis. We next asked whether valganciclovir prophylaxis
could prevent αPD-1/αCTLA-4-related hepatitis in predisposed
individuals. The 50th, 75th and 90th percentiles of time-to-
hepatitis in CMV-IgG+ patients were 24, 52 and 84 days,
respectively; therefore, we treated four CMV IgG+ CD4+
TEM≥16% patients receiving αPD-1/αCTLA-4 therapy with pro-
phylactic valganciclovir for between 4 and 23 weeks (Fig. 9a).
Two of these patients registered mild, transient transaminitis that
resolved without treatment, so were not diagnosed with hepatitis.
Hence, we observed no hepatitis in the four valganciclovir-treated
patients, whereas 15 of 17 (88.2%) CMV IgG+ CD4+ TEM≥16%
patients treated with αPD-1/αCTLA-4 and no valganciclovir
prophylaxis developed clinical hepatitis (Fig. 9b). To us, these
four cases are consistent with the idea that CMV plays an
important aetiological role in development of hepatitis after αPD-
1/αCTLA-4 therapy in a specific subset of patients.
Discussion
Our study seeks to explain why a subset of patients with advanced
melanoma is predisposed to hepatitis following immune check-
point blockade. In our model, metastatic disease promotes com-
partmentalised CMV reactivation in latently infected individuals,
possibly triggered by an unknown winter virus infection; in turn,
CMV stimulates expansion of CD4+ TEM cells prior to immu-
notherapy. When αPD-1/αCTLA-4 therapy is given, these TEM
cells might inflict liver injury directly or promote bystander T cell
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CMV IgG+ cases (n=40)
Fig. 5 CD4+ TEM cell expansion correlates with immunity to cytomegalovirus. a Seasonal presentation of CD4+ TEM≥21% patients between 2017 and
2020 (n= 103; F.E.). Dashed red line indicates a cut-off of CD4+ TEM≥ 21%. b CD4+ TEM≥21% status was associated with high serum levels of anti-CMV
IgG antibodies (n= 100; F.E.; p= 1.2 ⨯ 10−5). Dashed red line indicates a cut-off of CD4+ TEM≥ 21%. c CD4+ TEM≥21% status was associated with CMV-
reactivity in pp65 ELISPOT (n= 53; F.E.; p= 9.0 ⨯ 10−5). Dashed red line indicates a cut-off of CD4+ TEM≥ 21%. d Development of hepatitis was
associated with CMV-seropositivity and CD4+ TEM≥21% status (n= 89). Median values are indicated by a red line. e ROC analysis showing CD4+ TEM % is
a superior discriminator of patients at risk of hepatitis when considering only CMV IgG+ cases as opposed to all cases. f Classification of patients with
unresectable metastatic melanoma who did or did not develop αPD-1/αCTLA-4-related hepatitis according to CMV IgG status and baseline CD4+ TEM cell
frequency using a revised cut-off of CD4+ TEM≥ 16%. Red boxes indicate 34 of 40 (85%) cases correctly classified by our model (n= 40; F.E.; p= 1.4 ⨯
10−5). Green box indicates 2 of 17 (11.7%) cases predicted to develop hepatitis who did not. Pink box indicates 4 of 23 (17.4%) cases predicted not to
develop hepatitis who did. Blue box indicates 19 of 49 CMV IgG− patients not considered by our model who developed hepatitis.
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but salient example of a general mechanism responsible for
hepatitis after checkpoint blockade because other viruses or toxic
agents could also drive chronic CD4+ T cell activation before
therapy. We speculate anti-viral immunity might also explain
predisposition to other adverse reactions following αPD-1/
αCTLA-4 therapy, such as colitis or pneumonitis37. The
remarkable overlap between organs affected by tissue-invasive
CMV disease and those susceptible to immune-related adverse
reactions has not escaped our attention38,39.
Being able to identify patients predisposed to hepatitis opens
various possibilities for avoiding or preventing treatment-related
hepatitis40. Three of four CD4+ TEM≥21% patients assigned to
αPD-1 monotherapy instead of αPD-1/αCTLA-4-treatment did
not develop hepatitis as predicted; therefore, baseline CD4+ TEM
expansion could be taken as a relative contraindication to dual
therapy. However, a more promising strategy is to suppress occult
CMV reactivation. In our study, valganciclovir prophylaxis
apparently prevented hepatitis in four of four CMV IgG+ CD4+
TEM≥16% patients. This approach must be refined in terms of
dosing and duration of anti-viral therapy in randomised, con-
trolled clinical trials, but could potentially achieve the superior
outcomes of αPD-1/αCTLA-4 dual therapy over αPD-1 mono-
therapy with fewer complications.
Because baseline CD4+ TEM expansion was observed in
patients with metastatic disease, but not in patients with fully
resected melanoma, it is possible that disseminated melanoma
promotes low-level CMV reactivation, perhaps through com-
promised T cell immunity, which then stimulates virus-specific
CD4+ T cell expansion. The prominent association between
CD4+ TEM expansion and CMV (in contrast to other her-
pesgroup virus infections) might simply reflect differences in
tissue tropism and, we speculate, the capacity of compartmenta-
lised CMV reactivation in liver to drive especially strong T cell
responses. Seasonal variation in the incidence of CD4+ TEMhigh
cases suggests that environmental factors influence expansion and
contraction of the CD4+ TEM cell pool41,42. In particular, we
suspect common winter viruses somehow promote CMV reacti-
vation in liver.
Chronic, low-level exposure to viral antigens preferentially
expands TEM over TCM43–49, so CMV-reactive CD4+ T cell
expansion might be sustained by very little CMV replication. On-
going T cell reactions against CMV in CD4+ TEMhigh patients are
cb
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Fig. 6 CMV-reactive CD4+ T cells are enriched in patients with CD4+ TEM cell expansion. CMV-reactive CD4+ T cells in patients with unresectable
metastatic melanoma were assayed by in vitro stimulation with CMV lysates (blue boxes). Neutralising antibodies (red hatching) were used to detect
T cells unable to respond to CMV antigens owing to expression of PD-1 or CTLA-4. T cell responses were quantified by flow cytometry analysis of cytokine
expression. a Example data from a CMV IgG+ CD4+ TEM≥16% patient who developed hepatitis. Gating of live, singlet, IFN-γ-producing CD4+ T cells is
illustrated in Supplementary Fig. 11. b Frequencies of IFN-γ-producing CD4+ T cells in patients categorised according to CMV IgG serostatus and baseline
CD4+ TEM frequency (n= 42; two-way ANOVA with Tukey correction for multiple comparisons; n.s. = not significant). Boxplots represent the median,
25th and 75th percentiles, and Tukey whiskers. c Absolute numbers of circulating IFN-γ-producing CD4+ T cells patients categorised according to CMV
IgG serostatus and baseline CD4+ TEM frequency (n= 42; two-way ANOVA with Tukey correction for multiple comparisons; n.s. = not significant).
Boxplots represent the median, 25th and 75th percentiles, and Tukey whiskers.
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likely to suppress CMV replication almost completely. Our
inability to detect CMV in baseline serum samples from CD4+
TEMhigh patients or liver biopsies from patients with high-grade
hepatitis is a challenge for our theory; however, it may simply be
beyond our technical capability to detect very low levels of
compartmentalised viral reactivation. In our view, the strong
correlation between CMV-specific immunity and development of
hepatitis, as well as the apparent effectiveness of valganciclovir,
suggests a causal role for CMV in the aetiology of αPD-1/αCTLA-
4-related hepatitis.
We do not presently know whether CMV-specific CD4+ TEM
cells inflict liver injury directly or provoke bystander T cell
responses50. Administration of αPD-1 or αCTLA-4 has been
associated with CMV reactivation in colon, so it is probable that
CMV also reactivates in liver during dual therapy51. In two
patients with high-grade hepatitis, we observed liver inflamma-
tion subsided immediately after starting valganciclovir. In our
view, the likely presence of viral antigen and apparent respon-
siveness to valganciclovir is consistent with a direct pathological
effect of CMV-specific T cells, although we accept this will be
hard to prove in patients.
Better understanding the contribution of anti-viral T cell
immunity to checkpoint blockade-related adverse reactions leads
us to unexpected solutions for preventing serious complications
of cancer immunotherapy. From a clinical perspective, the
immunological mechanisms described illustrate how patients’
medical histories, especially prior exposure to pathogens, impact
















































Fig. 7 Case 1: valganciclovir treatment of late-onset αPD-1/αCTLA-4-related hepatitis. A 54-year-old male patient who received αPD-1 (Nivolumab)
plus αCTLA-4 (Ipilimumab) dual therapy for metastatic melanoma presented with late-onset hepatitis. a Course of treatment. b Change in hepatitis-related
parameters over time and their association with introduction, withdrawal and re-introduction of valganciclovir treatment. c The patient presented at the
end of week 40 with recrudescent hepatitis and was treated with 900mg/day valganciclovir for 2 days prior to liver biopsy. Histopathological image of the
liver biopsy (H&E staining; scale bar 500 µm). d Generally, the liver parenchyma appeared normal (H&E staining; scale bar 100 µm). e Only a few
lymphocytes and sparse necrotic hepatocytes were observed in portal areas with small bile plugs (arrows) with no signs of hepatitis (H&E staining; scale
bar 100 µm).
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Methods
Study approval and patient management. This study involving human research
participants was performed in accordance with the Declaration of Helsinki and all
applicable German and European laws and ethical standards. Specifically, speci-
mens were obtained from patients with Stage III or IV melanoma participating in a
single-centre observational clinical trial authorised by the Ethics Committee of the
University of Regensburg (approval 16-101-0125) and registered with clinicaltrials.
gov (NCT04158544). All participants gave full, informed written consent. The first
reported patient was recruited in October 2016 and the last reported patient was
recruited in July 2020. Patients received standard-of-care treatment according to
local guidelines (Fig. 1a). Stage IV patients with unresectable metastatic disease
who received first- or second-line checkpoint inhibitor therapy were initially
treated with Nivolumab (αPD-1; Bristol-Myers Squibb) and Ipilimumab (αCTLA-
4; Bristol-Myers Squibb) for four cycles, and thereafter with Nivolumab main-
tenance therapy (3 mg/kg at 3-week intervals). Those patients with complete
resection of Stage III melanoma who received adjuvant first-line checkpoint
inhibitor therapy were treated for up to 1 year with Pembrolizumab (αPD-1; MSD)
or Nivolumab.
Clinical flow cytometry. Detailed step-by-step protocols for preparation and
analysis (including specimen gating strategies) of clinical samples by flow cyto-
metry are available through Protocol Exchange52. In brief, peripheral blood sam-
ples were collected into ethylenediaminetetraacetic acid (EDTA)-vacutainers by
venepuncture and then delivered to the immune monitoring laboratory at ambient
temperature. Pre-analytical samples were stored for up to 4 h at 4 °C until pro-
cessing. Whole blood was stained with DuraClone reagents (Duraclone IM Phe-
notyping Basic Tube, B53309; Duraclone IM T cell Subsets Tube, B53328;
Duraclone IM TCRs Tube, B53340; Duraclone IM Treg Tube, B53346; Duraclone
IM B cells Tube, B53318; Duraclone IM Dendritic Cells Tube, B53351; all from
Beckman Coulter, Krefeld, Germany). Data were recorded with a NaviosTM cyt-

















































Fig. 8 Case 2: valganciclovir treatment of late-onset αPD-1/αCTLA-4-related hepatitis. A 49-year-old male patient who received αPD-1 (Nivolumab)
plus αCTLA-4 (Ipilimumab) dual therapy for metastatic melanoma presented with late-onset hepatitis. a Course of treatment. b Change in hepatitis-related
parameters over time and their association with introduction of valganciclovir treatment. c Histopathological image of a liver biopsy taken at the start of
week 72 showing signs consistent with drug toxicity, autoimmunity or viral infection (H&E staining; scale bar 500 µm). d Extensive centrilobular necrosis
(arrows) involving 30–40% of hepatocytes was observed (H&E staining; scale bar 100 µm). e Dense inflammatory infiltration of lymphocytes, eosinophils
and neutrophils was seen in portal areas (H&E staining; scale bar 100 µm).
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version 1.3 (Beckman Coulter). Blinded analyses were performed by an experi-
enced operator using Kaluza version 2.1 according to gating strategies illustrated in
Supplementary Figs. 2–8.
Detection of CMV-reactive T cells by flow cytometry. Detailed step-by-step
protocols are available through Protocol Exchange53. Briefly, frozen PBMC from
patients were thawed and resuspended in RPMI medium (ThermoFisher, Schwerte,
Germany) supplemented with 5% heat-inactivated pooled, male-only human AB
serum (ZKT Tübingen, Germany), 100 U/ml penicillin, 100 μg/ml streptomycin
and 2 mM Glutamax (ThermoFisher). Cells were plated in 96-well round-bottom
plates at 1 × 106 cells in 150 µl/well then incubated at 37 °C with 5% CO2. After 6 h,
cultures were stimulated with 5 µg/ml CMV Lysate (Origene) and αCD28/αCD49
for 18 h. In some conditions, cultures were treated with neutralising monoclonal
antibodies against PD-1 (MAB10864, R&D) plus CTLA‐4 (MAB3254, R&D) at 5
µg/ml each or mouse IgG1 isotype control (MAB002, R&D) at a final concentration
of 10 µg/ml. During the last 4 h of cell culture, protein secretion was blocked with
Protein Transport Inhibitor Cocktail (ThermoFisher) containing Brefeldin A und
Monensin. Cytokine production was then assessed by flow cytometry. Dead cells
were excluded with ViaKrome-808 Fixable Viability Dye (Beckman Coulter).
Staining was performed in Cell Staining Buffer (BioLegend) with 10% FcR Block
(Miltenyi). Cells were fixed and permeabilised using the eBioscience IC Fixation
Buffer and Permeabilization Buffer (eBiosciences, ThermoFisher). Data were
recorded with a Cytoflex LXTM cytometer running CytoExpert Software (Beckman
Coulter) and analysed using Kaluza version 2.1 (Beckman Coulter) according to
the gating strategy shown in Supplementary Fig. 11.
18F-FDG PET/CT imaging. Hepatic glucose metabolism as a measure of liver
inflammation34 was analysed retrospectively in all 32 patients who underwent pre-
treatment 18F-FDG positron emission tomography and computed tomography (PET-
CT) imaging as part of routine tumour staging shortly before starting immunother-
apy. After overnight fasting, whole-body PET acquisitions covering at least the trunk
were started 60–90min after i.v. injection of 18F-FDG (3MBq per kg body weight) on
a Biograph Sensation 16 LSO or Biograph mCT40 Flow PET/CT scanner (both
Siemens Healthcare, Germany) and lasted 18–24min depending on patient size. The
same area was covered by a low-dose CT scan (tube current <50mAs, tube voltage
120 kV) if no contrast agents were used. Otherwise 130ml of AccupaqueTM 300 (GE
Healthcare) was applied as intravenous contrast agent with consecutive full-dose CT
acquisition (120 kV, <100mAs). PET images (slice thickness 5 mm) were corrected
for random coincidences, decay, scatter, and attenuation and reconstructed iteratively
using vendor parameter presets. PET and CT images were checked for breathing
artifacts and scaled to standardised uptake values (SUV). SUVmean Blood was mea-
sured in a thread-like region-of-interest (ROI) manually set into the aorta and
SUVmean Liver in a spherical ROI in the right liver lobe using the program ROVER
(Version v3.0.35, Helmholtz-Zentrum Dresden-Rossendorf, Germany). SUR was
calculated as with correction for the distribution time T of 18F-FDG to the reference
time T0 of 75min post injection54: SUR= (T0/T) × (SUVmean liver / SUVmean blood).
Routine clinical investigations. Routine biochemical and haematological inves-
tigations were performed by an in-house accredited diagnostic laboratory (Institute
of Clinical Chemistry and Laboratory Medicine, UKR). Virological investigations
were conducted by an in-house accredited laboratory (Institute of Clinical
Microbiology and Hygiene, UKR) following routine diagnostic procedures. CMV-
reactive T cells were quantified by IFN-γ ELISPOT (Lophius, Germany) according
to the manufacturer’s instructions in an accredited laboratory (UKR).
Statistics, data transformations and visualisation. Significance tests and curve-
fitting were performed with GraphPad Prism 6.04 (GraphPad Software, Inc., La
Jolla, USA) or SPSS® version 25 (IBM Analytics, New York, USA). As indicated,
data were analysed using a two-tailed Mann–Whitney (M.W.) test, two-tailed
Fisher’s exact test (F.E.), D’Agostino & Pearson’s normality test (K2), one-way or
two-way ANOVA, two-tailed t-tests, log-rank survival analysis, receiver-operator
characteristic (ROC) analysis or calculating pairwise Pearson correlations (R2).
Where stated in the figure legends, p-values were adjusted for multiple comparison
using Benjamini–Hochberg (B.H.) correction or Bonferroni correction, but
otherwise no adjustment was made.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this study are available within the article and its
Supplementary information files, or are available from the corresponding author subject
to legal restrictions governing use of personal information. Source data are provided with
this paper.
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